Lung adenocarcinomas, which account for approximately 50% of NSCLC, are molecularly subclassified and subjected to different therapeutic strategies according to the presence of distinct alterations in genes such as EGFR, ALK, and KRAS [3]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.